EGFR and non-small cell lung carcinoma: More recently, CheckMate 722 showed no significant PFS improvement with nivolumab plus chemotherapy vs. chemotherapy alone in EGFR-mutant NSCLC after EGFR TKI progression (HR 0.75, 95% CI 0.56–1.00) [124].